Similar articles for PMID: 27418145

Year	Number of Results
1999	1
2003	1
2006	1
2007	1
2008	1
2011	3
2012	2
2013	6
2014	8
2015	10
2016	13
2017	12
2018	9
2019	9
2020	9
2021	14
2022	13
2023	6
2024	2

1

NETs: organ-related epigenetic derangements and potential clinical applications.

Cives M, Simone V, Rizzo FM, Silvestris F. Cives M, et al. Oncotarget. 2016 Aug 30;7(35):57414-57429. doi: 10.18632/oncotarget.10598. Oncotarget. 2016. PMID: 27418145 Free PMC article. Review.

2

Neuroendocrine tumours: cracking the epigenetic code.

Karpathakis A, Dibra H, Thirlwell C. Karpathakis A, et al. Endocr Relat Cancer. 2013 May 20;20(3):R65-82. doi: 10.1530/ERC-12-0338. Print 2013 Jun. Endocr Relat Cancer. 2013. PMID: 23429748 Review.

3

KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors.

Yuan F, Shi M, Ji J, Shi H, Zhou C, Yu Y, Liu B, Zhu Z, Zhang J. Yuan F, et al. Int J Biol Sci. 2014 Aug 30;10(9):957-65. doi: 10.7150/ijbs.9773. eCollection 2014. Int J Biol Sci. 2014. PMID: 25210493 Free PMC article.

4

DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors.

Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B, Kinzler KW, Hruban RH, Papadopoulos N. Jiao Y, et al. Science. 2011 Mar 4;331(6021):1199-203. doi: 10.1126/science.1200609. Epub 2011 Jan 20. Science. 2011. PMID: 21252315 Free PMC article.

5

Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.

Sun C, Estrella JS, Whitley EM, Chau GP, Lozano G, Wasylishen AR. Sun C, et al. Dis Model Mech. 2022 Aug 1;15(8):dmm049552. doi: 10.1242/dmm.049552. Epub 2022 Aug 26. Dis Model Mech. 2022. PMID: 35976056 Free PMC article.

6

Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours.

Pipinikas CP, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, Fusai G, Valente R, Caplin M, Meyer T, Teschendorff A, Bell C, Morris TJ, Salomoni P, Luong TV, Davidson B, Beck S, Thirlwell C. Pipinikas CP, et al. Endocr Relat Cancer. 2015 Jun;22(3):L13-8. doi: 10.1530/ERC-15-0108. Epub 2015 Apr 21. Endocr Relat Cancer. 2015. PMID: 25900181 Free PMC article. No abstract available.

7

Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.

Hackeng WM, Assi HA, Westerbeke FHM, Brosens LAA, Heaphy CM. Hackeng WM, et al. Surg Pathol Clin. 2022 Sep;15(3):541-554. doi: 10.1016/j.path.2022.05.007. Epub 2022 Aug 2. Surg Pathol Clin. 2022. PMID: 36049835 Review.

8

Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex.

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch DK, Ocker M, Quint K, Heverhagen AE. Geis C, et al. J Surg Res. 2015 Apr;194(2):388-393. doi: 10.1016/j.jss.2014.10.052. Epub 2014 Nov 5. J Surg Res. 2015. PMID: 25439321

9

DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.

Park JK, Paik WH, Lee K, Ryu JK, Lee SH, Kim YT. Park JK, et al. Oncotarget. 2017 Jul 25;8(30):49796-49806. doi: 10.18632/oncotarget.17964. Oncotarget. 2017. PMID: 28591701 Free PMC article.

10

Aberrant Menin expression is an early event in pancreatic neuroendocrine tumorigenesis.

Hackeng WM, Brosens LA, Poruk KE, Noë M, Hosoda W, Poling JS, Rizzo A, Campbell-Thompson M, Atkinson MA, Konukiewitz B, Klöppel G, Heaphy CM, Meeker AK, Wood LD. Hackeng WM, et al. Hum Pathol. 2016 Oct;56:93-100. doi: 10.1016/j.humpath.2016.06.006. Epub 2016 Jun 21. Hum Pathol. 2016. PMID: 27342911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year